Yonemura Y, Kamata T, Ohoyama S, Matumoto H, Kimura H, Kosaka T, Yamaguchi A, Miwa K, Miyazaki I
Department of Surgery II, School of Medicine, Kanazawa University, Japan.
Anal Cell Pathol. 1991 Mar;3(2):103-10.
The proliferative activities of 98 biopsied specimens of advanced gastric cancers were measured by the in vitro bromodeoxyuridine (BrdU) labelling method. BrdU labelling indices (LIs) varied from 4.8 to 45.1%. There was no correlation of BrdU LIs and histological type, distant metastasis, serosal invasion, macroscopic type or tumor size. However, BrdU LIs of tumors with lymph node metastases were significantly higher than those without them. Patients with tumors showing high BrdU LIs had a three-fold relative risk of death, as compared with those showing low BrdU LIs. When the BRdU LIs and all the clinicopathological parameters were entered simultaneously into the Cox model, BrdU LIs, peritoneal dissemination and serosal invasion emerged as independent prognostic parameters. These results indicate that the in vitro BrdU labelling method using biopsied materials may be useful in predicting lymph node metastasis preoperatively and designing operative procedures for individual patients.
采用体外溴脱氧尿苷（BrdU）标记法检测98例进展期胃癌活检标本的增殖活性。BrdU标记指数（LIs）在4.8%至45.1%之间。BrdU LIs与组织学类型、远处转移、浆膜侵犯、大体类型或肿瘤大小均无相关性。然而，有淋巴结转移的肿瘤的BrdU LIs显著高于无淋巴结转移的肿瘤。与BrdU LIs低的患者相比，BrdU LIs高的肿瘤患者的相对死亡风险高出三倍。当将BrdU LIs和所有临床病理参数同时纳入Cox模型时，BrdU LIs、腹膜播散和浆膜侵犯成为独立的预后参数。这些结果表明，使用活检材料的体外BrdU标记法可能有助于术前预测淋巴结转移并为个体患者设计手术方案。
